PHARMACOLOGY & THERAPEUTICS

Executive Editors
W. C. Bowman, A. M. Breckenridge, A. C. Sartorelli.

CHEMOTHERAPY

CLINICAL PHARMACOLOGY & THERAPEUTICS

TOXICOLOGY

METABOLIC INHIBITORS

GENERAL & SYSTEMATIC PHARMACOLOGY

Volume Contents, Author index and Subject index to Volume 16

L.
6
982

PERGAMON PRESS OXFORD · NEW YORK

PHARMACOLOGY & THERAPEUTICS

Chemotherapy, Toxicology and Metabolic Inhibitors

Executive Editor: A. C. Sartorelli

Yale University School of Medicine, Department of Pharmacology, 333 Cedar Street, New Haven, Connecticut 06510, USA

Managing Editor: Barbara Z. Renkin, Ph.D.

General and Systematic Pharmacology

Executive Editor: W. C. Bowman

University of Strathclyde, Department of Physiology & Pharmacology, Royal College, 204 George Street, Glasgow G1 1XW, Scotland

Clinical Pharmacology and Therapeutics

Executive Editor: A. M. Breckenridge

University of Liverpool, Department of Pharmacology & Therapeutics, P.O. Box 147, Liverpool L69 3BX, England

Editorial Board

G. E. Adams—*Sutton, Surrey, England*
S. Agoston—*Groningen, Netherlands*
Joseph R. Bertino—*New Haven, Connecticut*
R. T. Brittain—*Ware, Hertfordshire*
Ernest Bueding—*Baltimore, Maryland*
B. A. Callingham—*Cambridge, England*
Donald S. Coffey—*Baltimore, Maryland*
William A. Creasey—*Philadelphia, Pennsylvania*
P. F. D'Arcy—*Belfast, N. Ireland*
M. A. Denborough—*Canberra, Australia*
Robert L. Dixon—*Research Triangle Park, North Carolina*
Jurgen Drews—*Wien, Austria*
W. F. Dryden—*Edmonton, Alberta, Canada*
B. L. Furman—*Glasgow, Scotland*
George A. Galegov—*Moscow, USSR*
C. F. George—*Southampton, England*
Evgeny Golovinsky—*Sofia, Bulgaria*
Robert E. Handschumacher—*New Haven, Connecticut*
Peter Langen—*Berlin, GDR*
Åke Liljestrand—*Stockholm, Sweden*
Jerry Mitchell—*Houston, Texas*
A. Nies—*Denver, Colorado*
E. E. Ohnhaus—*Essen, German Federal Republic*
M. L'E. Orme—*Liverpool, England*
Robert E. Parks, Jr.—*Providence, Rhode Island*
Sidney Pestka—*Nutley, New Jersey*
William H. Prusoff—*New Haven, Connecticut*
J. L. Reid—*Glasgow, Scotland*
A. Richens—*London, England*
D. S. Savage—*Glasgow, Scotland*
D. G. Shand—*Durham, North Carolina*
David Shugar—*Warsaw, Poland*
F. Sjöqvist—*Huddinge, Sweden*
Jan Škoda—*Prague, Czechoslovakia*
A. Stafford—*Glasgow, Scotland*
Donald J. Tipper—*Worcester, Massachusetts*
E. S. Vesell—*Hershey, Pennsylvania*
George Weber—*Indianapolis, Indiana*
Gerhard Zbinden—*Zurich, Switzerland*

Library Annual Subscription Rates—published in 4 volumes per annum of 3 issues each.
Annual Subscription, 1983, U.S. $800.00 including postage and insurance. 2 years, 1983/84, U.S. $1520.00.
Specially Reduced Rates to Individuals: Any individual whose institution takes out a library subscription may purchase a second or additional subscription for personal use at a much reduced rate of $350.00 annually.
Subscribers to the Journal may claim a 20% discount off Encyclopedia volumes.

Subscription enquiries from customers in North America should be sent to: Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523, U.S.A. and for the remainder of the world to: Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England.

At the end of the year, the Subscriber will receive, free, both the annual subject index and an attractive and durable magazine binder, especially designed for *Pharmacology & Therapeutics*.

Copyright © 1982 Pergamon Press Ltd.

It is a condition of publication that manuscripts submitted to this journal have not been published and will not be simultaneously submitted or published elsewhere. By submitting a manuscript, the authors agree that the copyright for their article is transferred to the publisher if and when the article is accepted for publication. However, assignment of copyright is not required from authors who work for organisations which do not permit such assignment. The copyright covers the exclusive rights to reproduce and distribute the article, including reprints, photographic reproductions, microform or any other reproductions of similar nature and translations. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, electrostatic, magnetic tape, mechanical, photocopying, recording or otherwise, without permission in writing from the copyright holder.

U.S. COPYRIGHT LAW APPLICABLE TO USERS IN THE U.S.A.

The Article Fee Code on the first page of an article in this journal indicates the copyright owner's consent that in the U.S.A. copies may be made for personal or internal use provided the stated fee for copying beyond that permitted by Section 107 or 108 of the United States Copyright Law is paid. The appropriate remittance should be forwarded with a copy of the first page of the article to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970. If a code does not appear, copies of the article may be made without charge, provided permission is obtained from the publisher. The copyright owner's consent does not extend to copying for general distribution, for promotion, for creating new works or for resale. Specific written permission must be obtained from the publisher for such copying. In case of doubt please contact your nearest Pergamon office.

Microform Subscriptions and Back Issues

Back issues of all previously published volumes are available in the regular editions and on microfilm and microfiche. Current subscriptions are available on microfiche simultaneously with the paper edition and on microfilm on completion of the annual index at the end of the subscription year.

Publishing and Advertising Offices

Pergamon Press Ltd.
Headington Hill Hall
Oxford OX3 0BW
England

Pergamon Press Inc.
Maxwell House
Fairview Park, Elmsford
New York 10523, U.S.A.

Volume 16, 1982, Numbers 1–3

CONTENTS

Number 1 PAGE

The cardiac excitation–contraction cycle: *B. Wohlfart and M. I. M. Noble* 1
Insecticides affecting acetylcholine receptor interactions: *A. T. Eldefrawi, N. A. Mansour and M. E. Eldefrawi* 45
Structure–activity relationships of peptides derived from ACTH, β-LPH and MSH with regard to avoidance behavior in rats: *J. W. van Nispen and H. M. Greven* 67
Age-dependent changes in the effects of food toxins and other dietary factors on the eye: *D. S. McLaren* 103

Number 2

Kinetics of pharmacologic response: *N. H. G. Holford and L. B. Sheiner* 143
Plasma concentrations and therapeutic effect of anti-inflammatory and anti-rheumatic drugs: *M. L'E. Orme* 167
Vancomycin and related antibodies: *H. R. Perkins* 181
Bacitracin: *W. A. Toscano, Jr. and D. R. Storm* 199
Effects of pharmacological agents on general hemodynamics and peripheral circulation during fetal and postnatal development: *W. H. Harris* 211
Absorption of drugs and other xenobiotics during development in experimental animals: *H. Hoffman* 247
Drug metabolism in alcoholics: *O. Pelkonen and E. Sotaniemi* 261
The effects of nicotine on brain neurotransmitter systems: *D. K. J. Balfour* 269
Medical problems associated with tobacco smoking: *M. D. Clee and R. A. Clark* 283

Number 3

Strategy for the discovery and development of a positive inotropic agent: *D. B. Evans, R. E. Weishaar and H. R. Kaplan* 303
Ultrastructure and calcium exchange of the sarcolemma, sarcoplasmic reticulum and mitochondria of the myocardium: *G. A. Langer, J. S. Frank and K. D. Philipson* 331
Biotransformation of drugs and other xenobiotics during postnatal development: *W. Klinger* 377
Anorexia nervosa: its entity as an illness and its treatment: *G. L. Szmukler* 431
Psychological factors in human feeding: *J. Rodin and J. Marcus* 447

DL.
16
982

AUTHOR INDEX

Balfour, D. J. K. 269

Clark, R. A. 283
Clee, M. D. 283

Eldefrawi, A. T. 45
Eldefrawi, M. E. 45
Evans, D. B. 303

Frank, J. S. 331

Greven, H. M. 67

Harris, W. H. 211
Hoffman, H. 247
Holford, N. H. G. 143

Kaplan, H. R. 303
Klinger, W. 377

Langer, G. A. 331

Mansour, N. A. 45
Marcus, J. 447
McLaren, D. S. 103

Noble, M. I. M. 1

Orme, M. L'E. 167

Pelkonen, O. 261
Perkins, H. R. 181
Philipson, K. D. 331

Rodin, J. 447

Sheiner, L. B. 143,
Sotaniemi, E. 261
Storm, D. R. 199
Szmukler, G. L. 431

Toscano, W. A. Jr. 199

van Nispen, J. W. 67

Weishaar, R. E. 303
Wohlfart, B. 1

VOL
16
198

SUBJECT INDEX

Absorption of drugs
  and age 249–56
  injection 254
  mucosal 249–54
  skin 254, 255
Acetylcholine
  agonists 46
  antagonists 46
  nicotine effects 269, 270
  receptor and insecticides 45–60
  structure 46
Acrodermatitis enteropathica 119
Action potential
  calcium influx 13, 14
  currents in ventricular 7
  duration and contractile force 31
  duration and isomeric tension 29
  factors affecting restitution curves 30–2
  and force production 19
  membrane current contribution 10, 11
  outward current 10
  paired pulse stimulation and restitution 32
  rapid inward current 7, 8
  refractory period 27
  restitution 11, 27–32
  restituion curve and adrenaline 31
  restitution and stimulation interval 27–32
  slow outward current 8, 9
ACTH
  chain length, amino acid substitution and behavior 79–83
  fragment activity, Venn diagram 90
  alpha-helix $ACTH_{4-10}$ 92, 93
  isolation and characteristics 67, 68
  stereochemistry 79, 92, 93
Adiphenine 52
Adrenaline
  circulatory effects 212–14
  and restitution curve 31
Adrenergic agents, circulatory effects 215–17
Aequorin signal, calcium indicator 13
Age
  and food toxin effects on eye 103–36
  microcirculation features 249
  -related drug absorption 249–52
Alcohol
  acute effects 265, 266
  dehydrogenation 389
  drug-induced toxic reactions 266, 267
  inducing effects in alcoholics 263, 264
  liver damage 262
Alcoholism
  antipyrine elimination and liver damage 264
  and drug metabolism 261–7
  in vitro studies 262–5
  in vivo studies 263–5
  liver tests and drug metabolism 265
Amantadine 52
Amines, sympathetic and circulatory effects 217, 218
Aminorone
  inotropic effects 319, 322
  structure and characterization 306
Analgesic, plasma levels and effects 170, 171
Anorexia nervosa 431–43
  causal factors 440
  clinical features 432, 433
  definition 431, 432
  drug treatment 440–2
  epidemiology 433, 434
  family factors 434–6
  growth hormone 437
  hypothalamic–pituitary–adrenal axis 437, 438
  hypothalamic–pituitary–gonadal axis 436, 437
  hypothalamic–pituitary–thyroid axis 438
  menstruation induction 442, 443
  neurochemical hypothesis 438
  outcome 443
  psychological factors 434–6
  socio-cultural factors 434
  treatment approaches 439, 440
  weight history 441
ATPase; Ca : Mg 361–3
ATPase; Na : K and inotropic activity 312, 313
Avoparcin structure 185

Bacitracin 199–208
  antimicrobial spectrum 202, 203
  biosynthesis 201, 202
  C55-isoprenyl pyrophosphate binding 206
  divalent cation interaction 203, 204
  isolation and separation 199, 200
  lipid analog binding constants 207
  mechanism of action 203–8
  membrane permeability 204, 205
  metal ions and binding 207
  peptidoglycan synthesis 205–8
  polymyxin synergism 202
  structure 200, 201
  Zn-model 204
Bacillus lichiniformis peptides 199
Behavior
  acquisition and extinction 76, 77
  avoidance and peptide structure 67–96
  pole-jump avoidance extinction 77–9, 88–94
  shuttle box 74, 76
  tests for neuropeptides 72–5
Beta adrenoceptor stimulants 310
Biotin dependency 117
Biotransformation of drugs
  acetate conjugation 398, 407
  age effects 407
  amino acid conjugation 398
  BSP clearance 396, 397
  dealkylation 386–8
  dehydrogenation 389, 404
  enzyme induction 398–402

exchange reactions 391, 392
extrahepatic 403–7
glucuronidation 392–5, 406
glutathione conjugation 395–7, 406
hepatic 378–402
hydrolysis 390, 391, 405
hydroxylation of aromatics 384, 385
induction of activities 399–402
oxidative deamination 388, 389
oxidative reactions, cytochrome P-450 382–9, 403, 404
postnatal 377–408
reductive reactions 390, 404
regulation of development 407, 408
surface conjugation 397, 407
Bitot's spot and vitamin A 112
Blood pressure, model of factors controlling 157, 158
Bronchial carcinoma
genetic susceptibility 288
and smoking 287, 288
Bronchitis, smoking effects 284–7
Bulimia
nervosa 432 *see also* anorexia
treatment 442

Calcium
activator, metabolism model 32–9
activator, movements in excitation 13–18
contractile protein switch 11–13
efflux 18, 19
entry and contraction 14, 15
exchange, heart tissue 331–68
frog heart contractility 12
influx and myocardial excitation 13–15
mitochondrial uptake 365, 366
myocardial compartmentalization 368
release mechanism, intracellular store 15–17
sarcolemmal binding 316, 317
sarcolemmal pump 358, 359
sarcoplasmic reticulum pump 361–3
storage structures 5, 6
time-dependent transport 316
transporting membranes 3–7
transsarcolemmal movement control 354–8
Carbazeran
cardiovascular effects 319, 323
structure and characterization 308, 309
Carbohydrate deficiency, eye effects 109, 110, 123, 124
Cardiac excitation–contraction cycle 1–39 *see also* excitation–contraction
Cardiac failure
experimental models 325
future treatment 325, 326
and myocardial contractility 304
reversal by positive inotropic agents 304, 305
Cardiac fibres
length-dependent activation 25–7
length during contraction 27
length–tension relationship 24–7
tension activation and calcium 12
Cardiac glycosides 306, 307
mechanism of action 309, 310
use in pregnancy 223–5
Cardiac output, factors controlling 303
Cardiomyopathy, drug use in pregnancy 221–5
Cataract
diabetic 134
galactose 124
protein deficiency 122
riboflavin deficiency 116
senile 135, 136
Catecholamines
nicotine effects 270–4
and nicotine response 273, 274
release, turnover and nicotine 271–3
Chloroquine, plasma levels and effect 175, 176
Cholinergic agents, agonists and antagonists
circulatory effects 218, 219
Circulatory system, drug effects in development 211–38
Contractility
calcium metabolic model 34–6
control 358
determinants 34–6
postextrasystolic potentiation decay 36, 37
sarcomere length 21, 22
tension and previous contraction 35
Coronary artery atheroma and smoking 292
Coronary heart disease
mortality, morbidity and smoking 292, 293
and smoking 291, 292
Cystinosis, retinal pigment 122

DDT structure and acetylcholine receptors 57, 58
Development
drug effects on circulation 211–38
drug effects on experimental animals 247–56
regulation 407, 408
Diabetes mellitus, eye effects 132–4
Diazoxide and preterm labor 237
Digoxin
and electromechanical systole 146
structure and characteristics 306, 307
Dihydralazine, use in pregnancy 222, 223
Distribution equilibrium 167, 168
Dobutamine structure and characteristics 306, 307
Dopamine, circulatory effects 214, 215
anti-inflammatory 167–77
anti-rheumatic 167–77
assay methods and properties 168, 169
beta-blockers 221, 222
beta-sympathomimetic 234–6
catecholamines and circulation 212–15
clinical effect measurement 168
combinations and effects 162, 163
corticosteroids 175
and development in experimental animals
effect on circulation and hemodynamics in development 211–38
inotropic *see* positive inotropic agents
NSAID 171–5
plasma concentration and effects 167–77
postnatal biotransformation 377–408 *see also* biotransformation
therapeutic and toxic ranges 169, 170
use in pregnancy 221–5
Ductus arteriosus
closure and indomethacin 232–4
indomethacin effects 232–4
prostaglandin effects 227, 228
Ductus venosus, autonomic nervous system control 221

Emphysema, smoking effects 289, 290
Ethanol and preterm labour 236

Excitation–contraction coupling
energetics 2, 3
sarcolemma role 350–9
sarcoplasmic reticulum role 359–64
Excitation–contraction process 1, 2
Eye
adult dietary effects 126–32
carbohydrate deficient 109, 110, 123, 124
cholesterol plaques 136
dietary toxin effects 130–2
effects of senescence 132–6
ethanol effects 110, 111
food toxin effects and age 103–36
inanition effects 103, 104
lipid deficiency 124–6
mineral deficiency 108
mineral deficiency, postnatal 118–20
prenatal deficiencies 104–11
protein deficiencies 108–10, 120–3
sclerosis and hyperchromatism 117
sweeteners 111
vitamin deficiencies 104–8, 111–18, 127, 128
vitamin A effects 111–15
vitamin B complex effects 115–17

Feeding and feeding behavior
arousal 450–4, 456, 462
cognitions 453, 459
conditioning processes 449, 455, 456
distortion of regulation control 454–60
external cues 448–50, 454, 462
internal signals 447, 448, 454, 462
normal, regulation 447–54
and palatability 450, 451, 456–8, 461, 462
psychological factors 447–63
variability 458, 459
Feeding behavior and obesity 460–2
Folic acid, prenatal effects on eye 106, 107
Food, regulation of normal intake 447–54
Food toxins and age, eye effects 103–36
Force–velocity–activity relationship 19–23
hypothetical 21
length dependence 23–7
Force-velocity curve 20

Galactosemia and lens opacification 125
Gastrointestinal tract
age-related drug absorption 249–52
drug absorption and development 247–52
Glutathione
protective effects 395
transferase development 396
Gold, plasma levels and effects 176
Growth retardation, autonomic nervous system effects 221

Hemodynamics, pharmacological agent effects in development 211–38
Homocystinuria and lens dislocation 123
Hormone relations in anorexia 436–8
5-Hydroxytryptamine
and behavioral response to nicotine 278
brain levels and stress with nicotine 277
and neuroendocrine nicotine responses 277
nicotine effects on release and turnover 275–7
Hyperbilirubinemia, treatment by enzyme induction 399
Hypercholesterolemia, familial 135
Hypertension and drug use in pregnancy 221–5
Hypervitaminosis A, eye effects 106
Hypophysectomy, acquisition studies 74

Inanition
effects in adult eye 126, 127
eye effects 103, 104
Indomethacin
and ductus arteriosus 231, 232
ductus arteriosus closure 232–4
perinatal effects 229–34
plasma levels and effects 173, 174
pulmonary vascular resistance 230
umbilicoplacental vascular resistance 230, 231
Inhibitor, acetylcholine receptor function 51–3
Insecticides, acetylcholine receptor interactions 53–60
carbamates 53–5
cartrap 56, 57
DDT and chlorinated hydrocarbons 57, 58
nereistoxin 56, 57
nicotine 55, 56
organic mercurials 58, 59
organophosphorus 53–5
Ionophores, mechanism of action 310, 311
Iron, eye effects
deficiency and overload 129
Isoproterenol 319, 321–3

Keratomalacia and vitamin A 113
Kinins, perinatal effects 225, 226

Lipid deficiency, eye effects 124–6
Liver, postnatal drug biotransformation
enzyme induction 398–402
excretion 381, 382
storage 381
transport mechanisms 380–2
Local anaesthetics, perinatal effects 237
β-LPH, amino acid sequence 69
Lung
drug absorption and age 252, 253
function and smoking 290, 291

Membranes
isolated myocardial, properties 6, 7
myocardial, calcium transporting 3–7
Mercurial compounds and acetylcholine receptors 58–60
Methyldopa use in pregnancy 223
Minerals, post-natal deficiency, eye effects 118–20
Mitochondria, cardiac
calcium efflux 366, 367
calcium uptake 365, 366
functional significance 367, 368
ischemic appearance 350
ultrastructure 348–50
Model
calcium activator metabolism 32–9
calcium flow diagram 33
calcium force frequency relationship 37, 38
heart failure 325
ionotropic effects 38, 39
mechanical behavior in ventricular cells 23
physiological 157, 158
Zn-bacitracin A 204